A DmdA enzyme mutant and its application in the catalytic preparation of 5-methyltetrahydrofolate

By constructing a DmdA gene mutant library and expressing it in a host strain, the folic acid metabolic pathway was optimized, solving the problems of catalytic efficiency and stability of DmdA enzyme in the industrial preparation of 5-methyltetrahydrofolate, and achieving efficient and stable enzymatic preparation.

CN123107956APending Publication Date: 2026-11-17SHENZHEN HYGIEIA BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611620333.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-20
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

In existing technologies, the catalytic efficiency and thermal stability of DmdA enzyme in non-natural substrate environments cannot meet the requirements for industrial enzymatic preparation of 5-methyltetrahydrofolate, resulting in high production costs and low efficiency.

Method used

A DmdA gene mutation library was constructed using error-prone PCR technology. DmdA mutants with high enzyme activity were screened out. By combining random saturation mutation and combined multiple mutation optimization, DmdA enzyme mutants with high enzyme activity were obtained and expressed in Escherichia coli, Bacillus subtilis or Corynebacterium glutamicum to optimize the folic acid metabolism pathway and improve catalytic efficiency and stability.

Benefits of technology

The DmdA enzyme mutant was found to efficiently catalyze 5-methyltetrahydrofolate, significantly improving enzyme activity and temperature tolerance, making it suitable for various industrial applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107956A_ABST
    Figure CN123107956A_ABST
Patent Text Reader

Abstract

This invention discloses a DmdA enzyme mutant and its application in the catalytic preparation of 5-methyltetrahydrofolate. The enzyme mutant of this invention undergoes any one of the following amino acid mutations in the amino acid sequence shown in SEQ ID NO. 2: T96I, T96A, T96C, T96L, T96V, T96Q, N234A, N234L, N234T, N234M, I135A, I135K, I135M, I135Q, S266M, S266E, S266L, G317S, G317T, G317V, G317W, G317L, G317I, T96I-N234L, T96I-G317T, N234L-G317T, T96I-N234L-G317T. The DmdA enzyme mutant of the present invention has high catalytic efficiency and significant advantages in the synthesis of 5-MTHF.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of enzyme engineering technology, specifically relating to a DmdA enzyme mutant and its application in the catalytic preparation of 5-methyltetrahydrofolate. Background Technology

[0002] 5-Methyltetrahydrofolate (5-MTHF) is the main active form of folic acid in the human body. As a methyl donor, it participates in a variety of key physiological metabolic processes and is widely used in food fortification, dietary supplements, and pharmaceutical intermediates. Currently, the preparation methods of 5-MTHF mainly include three categories: chemical synthesis, chemical-enzymatic synthesis, and biosynthesis.

[0003] Chemical synthesis is currently the main method for the industrial production of 5-MTHF. This method typically uses folic acid as a starting material, synthesizing the target product through reduction, methylation, and resolution steps. Specifically, folic acid is first catalytically hydrogenated to tetrahydrofolate (THFA), then reacted with formaldehyde to undergo methyleneization to generate 5,10-methylenetetrahydrofolate, which is further hydrogenated to obtain 5-methyltetrahydrofolate. Finally, chiral resolution yields the biologically active (6S)-5-methyltetrahydrofolate. In recent years, researchers have continuously improved this process, for example, by introducing sodium dithionite (Sodium hydrosulfite) as a reducing agent and replacing aqueous solutions with citrate-disodium hydrogen phosphate buffer solutions to improve yield and product purity. There are also reports of using continuous flow processes to achieve a three-step tandem synthesis from folic acid to 5-MTHF. However, chemical synthesis methods generally suffer from inherent drawbacks such as cumbersome reaction steps, low chiral resolution efficiency, difficulty in ensuring optical purity, and large amounts of organic solvents used, resulting in high industrial production costs and environmental unfriendliness.

[0004] Chemical-enzymatic synthesis is an alternative route that has developed in recent years. Its core strategy combines chemical reduction steps with enzymatic stereoselective reduction steps. A typical process involves first reducing folic acid to dihydrofolate (DHFA) with a chemical reducing agent such as zinc powder, then using dihydrofolate reductase (DHFR) in the presence of a coenzyme NADPH regeneration system to stereoselectively reduce DHFA to (6S)-tetrahydrofolate, and finally converting it to (6S)-5-methyltetrahydrofolate via chemical methylation. This method improves the optical purity of the product to some extent, but it still relies on chemical reduction and chemical methylation steps and requires a continuous supply of exogenous coenzyme regeneration system, increasing process complexity and production costs.

[0005] Biosynthetic processes primarily rely on microbial fermentation or enzyme-catalyzed reactions. Current biosynthetic routes mainly depend on 5,10-methylenetetrahydrofolate reductase (MTHFR) catalyzing the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. Researchers have attempted to increase yields by constructing multi-enzyme cascade reaction systems or overexpressing multiple key enzymes in the folate-to-5-MTHF pathway. However, MTHFR, as the core enzyme of this route, suffers from problems such as stringent coenzyme dependence, poor substrate tolerance, insufficient activity in industrial reaction systems, and low product yields, resulting in high industrial production costs.

[0006] To overcome the aforementioned shortcomings, alternative enzymes have been explored in this field as catalytic solutions. Dimethylsulfoniopropionate inner salt-dependent demethylase A (DmdA, EC2.1.1.269) is a naturally occurring enzyme derived from marine α-proteobacteria (e.g., Pelagibacter ubique). DmdA theoretically possesses the potential to catalyze the synthesis of 5-MTHF; the catalytic mechanism is described in [link to relevant documentation]. Figure 1 However, the catalytic efficiency and thermal stability of naturally derived DmdA in non-natural substrate environments cannot yet meet the requirements for industrial enzymatic preparation.

[0007] Therefore, there is an urgent need in this field to obtain DmdA mutants modified by protein engineering to improve enzyme activity and stability, and to achieve efficient enzymatic preparation of 5-methyltetrahydrofolate. Summary of the Invention

[0008] To overcome the shortcomings of the prior art, this invention provides a DmdA enzyme mutant and its application in the catalytic preparation of 5-methyltetrahydrofolate. This invention constructs a DmdA gene mutant library using error-prone PCR technology, screens for DmdA mutants with high enzyme activity, and combines random saturation mutation and combined multiple mutation optimization to obtain a DmdA enzyme with high enzyme activity.

[0009] The technical solution adopted by this invention to solve its technical problem is: This invention provides a DmdA enzyme mutant, wherein the mutant undergoes any one of the following amino acid mutations in the amino acid sequence shown in SEQ ID NO. 2: T96I, T96A, T96C, T96L, T96V, T96Q, N234A, N234L, N234T, N234M, I135A, I135K, I135M, I135Q, S266M, S266E, S266L, G317S, G317T, G317V, G317W, G317L, G317I, T96I-N234L, T96I-G317T, N234L-G317T, T96I-N234L-G317T.

[0010] The present invention provides a nucleic acid molecule, which is a nucleic acid sequence encoding the above-mentioned DmdA enzyme mutant.

[0011] The present invention provides a recombinant expression vector comprising the above-mentioned nucleic acid molecules.

[0012] The present invention provides an engineered bacterium comprising the above-mentioned nucleic acid molecules and / or the above-mentioned recombinant expression vector.

[0013] Preferably, the engineered bacteria use Escherichia coli, Bacillus subtilis, or Corynebacterium glutamicum as the host strain.

[0014] This invention provides the application of the above-mentioned DmdA enzyme mutant or the above-mentioned engineered bacteria in the preparation of 5-methyltetrahydrofolate (5-MTHF).

[0015] This invention provides a method for preparing 5-methyltetrahydrofolate, which uses the above-mentioned DmdA enzyme mutant and dihydrofolate reductase to catalyze the preparation of 5-methyltetrahydrofolate from folic acid.

[0016] Preferably, the reaction system further includes dimethyl mercaptopropionic acid inner salt and / or (2-carboxyethyl) dimethyl sulfonium chloride.

[0017] Preferably, the reaction system further includes ADH enzyme, a reducing agent (such as isopropanol), and NADP+.

[0018] The beneficial effects of this invention are: The DmdA enzyme mutant of the present invention has high catalytic efficiency and has significant advantages and industrial value in the synthesis of 5-MTHF.

[0019] The DmdA enzyme mutant of the present invention has strong temperature tolerance, a wide operating temperature range, and can be used in a variety of different scenarios. Attached Figure Description

[0020] Figure 1 This is a diagram illustrating the catalytic mechanism of the DmdA enzyme-catalyzed synthesis of 5-MTHF in this invention.

[0021] Figure 2 This is a map of the recombinant plasmid T96I-N234L-G317T, a three-site combination mutant of Example 4 of the present invention.

[0022] Figure 3 This is a tertiary structure diagram of the three-point combination mutant T96I-N234L-G317T in Example 4 of the present invention.

[0023] Figure 4 This is the liquid phase spectrum of the blank control group after the catalytic reaction in Example 6 of the present invention.

[0024] Figure 5This is the liquid phase spectrum of the T96I-N234L-G317T mutant after catalytic reaction in Example 6 of the present invention. Detailed Implementation

[0025] The present invention will be further described below with reference to embodiments.

[0026] The following will clearly and completely describe the concept, specific solutions, and technical effects of the present invention with reference to embodiments, so as to fully understand the purpose, features, and effects of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, not all of them. Other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are all within the scope of protection of the present invention. The various technical features in the present invention can be combined interactively without contradicting each other.

[0027] Unless otherwise specified in the examples, the procedures should be performed under standard conditions or conditions recommended by the manufacturer. Reagents or instruments whose manufacturers are not specified are all commercially available products.

[0028] The core of this invention lies in providing a DmdA enzyme mutant with high enzyme activity, the gene encoding the DmdA enzyme mutant, an engineered bacterium containing the gene, and a construction method. This invention significantly enhances the catalytic activity, substrate affinity, and enzyme stability of the DmdA enzyme by performing targeted mutations at key sites in the wild-type DmdA gene, thereby increasing the yield of 5-methyltetrahydrofolate and achieving efficient biosynthesis of 5-MTHF.

[0029] The DmdA enzyme mutant of the present invention can be a single mutation site (such as T96I, N234L, G317T), a combination of two mutation sites (such as T96I-N234L, T96I-G317T, N234L-G317T), or a simultaneous mutation of three mutation sites (such as T96I-N234L-G317T).

[0030] The amino acid sequence of the DmdA enzyme mutant with the highest catalytic activity in this invention is shown in SEQ ID NO.19.

[0031] This DmdA enzyme mutant was obtained by mutating three key sites, as shown below. These mutations significantly enhance enzyme activity. (1) Position 96: Threonine Thr (T) → Isoleucine Ile (I) (T96I): The wild-type enzyme has a polar hydrophilic threonine (T) at position 96, which is located at a critical position at the entrance of the substrate binding pocket of the DmdA enzyme. The polar residues in the wild-type enzyme readily form hydrogen bonds with water molecules in the aqueous environment, occupying the substrate binding cavity and hindering the entry of hydrophobic substrates into the catalytic center, resulting in a high substrate Km value and weak substrate binding ability of the wild-type enzyme. This invention mutates it to hydrophobic isoleucine (I), completely eliminating the hydrophilic effect of the site, reshaping the local hydrophobic microenvironment of the binding pocket, reducing the water molecule occupation in the binding cavity, accurately adapting to the hydrophobic framework structure of the substrate, significantly improving the enzyme's recognition and binding ability to methyl donors, reducing the substrate binding energy barrier, and effectively improving the initial catalytic efficiency of methyl transfer.

[0032] (2) Position 234: Asparagine Asn (N) → Leucine Leu (L) (N234L): The wild-type position 234 is polar asparagine (N), which is adjacent to the substrate-specific binding region of tetrahydrofolate (THF) and is a key residue for regulating THF anchoring and fixing the spatial conformation of the substrate. The wild-type polar residue is more flexible and cannot stably fix the THF substrate, which easily leads to THF conformation shift and methyl transfer pairing misalignment during catalysis, resulting in decreased catalytic efficiency and increased probability of side reactions. In this invention, it is mutated to hydrophobic rigid leucine (L), which stabilizes the spatial conformation of the THF substrate in the catalytic center by enhancing the hydrophobic stacking effect of the region, locks the optimal catalytic posture of the substrate, greatly improves the accuracy of methyl transfer pairing between the methyl donor and THF, and significantly improves the generation efficiency and reaction specificity of 5-methyltetrahydrofolate.

[0033] (3) Position 317: Glycine (G) → Threonine (T) (G317T): In the wild type, position 317 is glycine (G). Glycine has no side chain groups and is the most flexible amino acid in the protein. This position is located in the flexible region of the C-terminal backbone of the DmdA enzyme. The wild type has excessive flexibility at this position, resulting in a loose overall protein structure. Under in vitro industrial catalytic temperature and pH fluctuations, it is prone to conformational dissociation, causing enzyme inactivation, poor catalytic stability, and inability to adapt to industrial reaction systems. This invention mutates it to threonine (T) with a polar side chain, introducing specific intramolecular hydrogen bonds, effectively restricting the disordered swinging of the C-terminal backbone, tightening the overall spatial conformation of the protein, significantly improving the thermal stability of the DmdA mutant, broadening the industrial catalytic reaction window, and ensuring stable activity for long-term continuous catalysis.

[0034] Construction scheme of engineered bacteria in this invention: The engineered bacteria use Escherichia coli, Bacillus subtilis, and Corynebacterium glutamicum as host strains. The high-enzyme-activity DmdA gene mutants (such as DmdA enzyme mutants containing 3 mutation sites) are integrated into the host strain genome or introduced into the host strain through expression vectors to achieve efficient expression of DmdA gene mutants. At the same time, the auxiliary genes related to 5-MTHF synthesis in the host strain can be optionally overexpressed or knocked out to optimize the folic acid metabolism pathway, reduce the accumulation of by-products, and further improve the synthesis efficiency of 5-MTHF.

[0035] Furthermore, the host strain is Escherichia coli BL21(DE3), Bacillus subtilis BS168, or Corynebacterium glutamicum ATCC13032, preferably Escherichia coli BL21(DE3), which has advantages such as fast growth rate, short fermentation cycle, clear genetic background, and easy gene modification, making it suitable for large-scale industrial fermentation production.

[0036] Furthermore, the accessory genes include genes related to the folic acid precursor pathway and genes related to the 5-MTHF degradation pathway; wherein, the genes related to the folic acid precursor pathway include folE (encoding GTP cyclase IA), folP (encoding dihydropteroate synthase), and puru (encoding phosphoribosylaminoimidazolium succinate synthase), and overexpression of the above genes can enhance the flux of the folic acid metabolic pathway and increase the supply of tetrahydrofolate precursors; the genes related to the 5-MTHF degradation pathway include metE (encoding methionine synthase), and knocking out the metE gene can reduce the consumption of 5-MTHF and increase the accumulation of 5-MTHF.

[0037] The method for constructing the dimethylmercaptopropionic acid inner salt-dependent demethylase A mutant and engineered bacteria encoded by the high-enzyme-activity DmdA gene mainly includes the following steps: (1) Obtaining the DmdA gene fragment: The target DmdA gene fragment was synthesized and ligated into the Pet28a plasmid. The gene synthesis was entrusted to Qingke Biotechnology. The C-terminus of the sequence was tagged with His to obtain the target wild-type gene fragment.

[0038] (2) Construction of DmdA gene mutation library: Using the synthesized DmdA gene fragment as a template, the error-prone PCR reaction system was optimized, and a mutant Taq enzyme and special reaction buffer were used to obtain the DmdA gene fragment containing random point mutations through random mutagenesis amplification. After recovery and purification, it was used for library construction.

[0039] (3) Screening of DmdA gene mutant library: Transformed single colonies were inoculated into 24-well plates for culture. When the OD600 of the cells reached 0.6-0.8, 0.5 mmol / L IPTG was added to induce expression. After continuous culture for 12-16 h, the cells were collected by centrifugation. Super lysis solution (Cell-Ruicheng) was added at a ratio of cells (g) / lysis solution (ml) = 1:10. Then, tetrahydrofolate substrate and methyl donor substrate (such as (2-carboxyethyl)dimethylsulfonium chloride) were added to the lysis system for enzymatic reaction. The yield of 5-MTHF was detected by liquid chromatography, and high-efficiency mutant strains with significantly improved catalytic efficiency were screened.

[0040] (4) Random saturation mutation and site-directed mutation: Random saturation mutation was carried out on the three core advantageous single mutation sites obtained in the initial screening to verify the enzyme activity enhancement effect of each single mutation; further, specific site-directed mutation primers were designed to construct different combinations of mutants in sequence, and T96I-N234L, T96I-G317T, N234L-G317T and the three-site superposition mutant T96I-N234L-G317T were obtained for subsequent enzyme activity re-screening and performance evaluation.

[0041] Experimental materials: Host strains: Escherichia coli BL21 (DE3), Escherichia coli DH5α, Bacillus subtilis BS168, Corynebacterium glutamicum ATCC13032; Vectors: cloning vector pMD19-T, expression vector pET-28a, pxmj119, pHT43; Enzymes: Taq enzyme, restriction endonucleases (NcoI, XhoI), T4 DNA ligase, DpnI; Reagents: Glucose, yeast extract, peptone, kanamycin, folic acid, tetrahydrofolate (THF), 5-MTHF standard, plasmid extraction kit, PCR purification kit, gel extraction kit, IPTG, NADP+, isopropanol, (2-carboxyethyl)dimethylsulfonium chloride, DTT; Instruments: PCR instrument, high-speed centrifuge, constant temperature shaker, bioreactor, high performance liquid chromatograph (HPLC), enzyme-linked immunosorbent assay (ELISA) reader, protein quantification kit, ultrasonic disruptor.

[0042] Example 1 Amplification of the DmdA gene fragment: The optimized sequence of the universal biological codon was used as the template for the DmdA gene, as shown in SEQ ID NO.1. The amino acid sequence of the dimethylmercaptopropionic acid inner salt-dependent demethylase A encoded by the DmdA gene is shown in SEQ ID NO.2. The upstream primer F1 (as shown in SEQ ID NO.3): 5'-CCATGGCCTCCATCTTTCCGAGCC-3' (containing the NcoI restriction site CCATGG) and the downstream primer R1 (as shown in SEQ ID NO.4): 5'-CTCGAGACGCCAGAAACCTTCAC-3' (containing the XhoI restriction site CTCGAG) were designed. PCR amplification was performed using the DmdA gene template. The PCR reaction conditions were: 94℃ pre-denaturation for 5 min; 94℃ denaturation for 30 s, 55℃ annealing for 30 s, 72℃ extension for 1 min, for a total of 30 cycles; final extension at 72℃ for 10 min. The PCR product was verified by 1% agarose gel electrophoresis, and the 1100 bp DmdA gene fragment was recovered and purified for later use.

[0043] SEQ ID NO.1: SEQ ID NO.2: MASIFPSRRVRRTPFSAGVEAAGVKGYTVYNHMLLPTVFDSLQADCAHLKEHVQVWDVACERQVSIQGPDALRLMKLISPRDMDRMADDQCYYVPTVDHRGGMLNDPVAVKLAADHYWLSLADGDLLQFGLGIAIARGFDVEIVEPDVSPLAVQGPRADDLMARVFGEAVRDIRFFRYKRLAF QGVELVVARSGWSKQGGFEIYVEGSELGMPLWNALFAAGADLNVRAGCPNNIERVESGLLSYGNDMTRENTPYECGLGKFCNSPEDYIGKAALAEQAKNGPARQIRALVIGGEIPPCQDAWPLLADGRQVGQVGSAIHSPEFGVNVAIGMVDRSHWAPGTGMEVETPDGMRPVTVREGFWRLE.

[0044] Example 2 Construction of DmdA gene mutation library: (1) Error-prone PCR amplification: Using the 1100bp DmdA gene fragment recovered in Example 1 above as a template, the PCR system was adjusted (dNTP concentration was 0.2 mmol / L, Mg 2+ The concentration was 7 mmol / L, and 0.5 mmol / L Mn was added. 2+ Add Taq enzyme (2×Rapid Taq Master Mix), and perform PCR amplification using primers F1 and R1 to obtain the DmdA gene fragment with point mutation; the PCR reaction conditions are the same as in Example 1, and the mutated DmdA gene fragment is recovered.

[0045] (2) Enzyme digestion and ligation: The mutated DmdA gene fragment and pET-28a vector were digested with restriction endonucleases NcoI and XhoI, respectively, at 37℃ for 2 h. The digested DmdA gene fragment and linearized pET-28a vector fragment were recovered. The two were ligated with T4 DNA ligase and ligated overnight at 16℃ to construct the recombinant expression vector.

[0046] (3) Library construction: The above recombinant expression vector was transformed into Escherichia coli DH5α competent cells, plated on LB solid medium containing kanamycin (50 μg / mL), and cultured at 37℃ for 12 h. All single colonies were picked, plasmids were extracted, and DmdA gene mutant library was obtained. The plasmid mutant library was transformed into Escherichia coli BL21 competent cells, plated on LB solid medium containing kanamycin (50 μg / mL), and cultured at 37℃ for 12 h to obtain transformants for screening.

[0047] Example 3 Screening of DmdA gene mutation libraries: (1) Induction of expression: The transformants of Example 2 were picked into 24-well plates, and 3 ml of LB liquid medium (containing 50 μg / mL kanamycin) was added to each well. The plates were cultured at 37°C and 200 rpm until the OD600 was 0.8. Then, 0.5 mM IPTG was added and the plates were induced to express for 12 h at 30°C.

[0048] (2) Catalytic reaction and screening: After induction for 12 h, the OD600 of the bacterial solution was measured, and the precipitate was collected by centrifugation and washed twice with sterile water. The super lysis buffer (Cellrui) was added at a ratio of bacterial cells (g) / lysate (ml) = 1:10. 300 μl was added to the reaction system, followed by the addition of 1 mM tetrahydrofolate and 1.2 mM (2-carboxyethyl) dimethyl sulfonium chloride. The mixture was then made up to the preset volume (1 ml) with buffer (PBS, pH 7.4). The reaction was carried out at 30 °C for 1 h. After shaking, the mixture was diluted 10 times and analyzed by liquid chromatography.

[0049] (3) Screening principle: A high-throughput screening system of whole cells and crude enzyme lysis buffer was used, with the ability to catalyze the production of L-5-methyltetrahydrofolate as the screening index. Transformants were induced to express in 24-well plates, and the DmdA mutant protein was expressed intracellularly in E. coli. After collection, washing, and lysis with super lysis buffer, the intracellular DmdA enzyme mutant protein was released. The methyl acceptor tetrahydrofolate (final concentration 1 mM) and the methyl donor (2-carboxyethyl) dimethylsulfonium chloride (final concentration 1.2 mM) were added to the reaction system, and the methyl transfer reaction was carried out under the conditions of PBS buffer pH 7.4 and 30℃.

[0050] The enzyme activity of DmdA enzyme expressed by different transformants is shown in Table 1.

[0051] Table 1:

[0052] It can be seen that the mutants corresponding to T96I, N234A, G317S, I135A, and S266M all have increased enzyme activity relative to the wild type.

[0053] Example 4 Random saturation mutation and site-directed combinatorial mutation: (1) Random saturation mutagenesis: Using the candidate mutants (T96I, N234A, G317S, I135A, S266M) screened in Example 3 as templates, saturation mutagenesis primers for each mutation site were designed, and random saturation mutagenesis PCR was performed to construct saturation mutation libraries for each site. The optimal single-site mutants for each site were further screened. The saturation mutagenesis primers for each mutation site are as follows: DmdA-T96I random saturation mutant primers: DmdA-T96I-F (SEQ ID NO.5): GTTCCANKKGTTGACCACCGTGGTGGCATGCTGAAC; DmdA-T96I-R (SEQ ID NO. 6): CGGTGGTCAACMMNTGGAACGTAGTAGCACTGGTCGTCAGC; DmdA-N234A random saturation mutant primers: DmdA-N234A-F (SEQ ID NO.7): GTCCGAACNKKATCGAACGTGTTGAATCTGGTCTGCTGTCT; DmdA-N234A-R (SEQ ID NO. 8): CGATMMNGTTCGGACAGCCCGCACGAACGTTCAGATCTG; DmdA-I135A random saturation mutant primers: DmdA-I135A-F (SEQ ID NO.9): GGTATCGCGNKKGCTCGTGGTTTCGATGTTGAAATCGTAG; DmdA-I135A-R (SEQ ID NO. 10): ACCACGAGCMMNCGCGATACCCAGACCGAACTGCAGAAG; DmdA-S266M random saturation mutant primers: DmdA-S266M-F (SEQ ID NO. 11): CTGCAACNKKCCGGAGGACTACATCGGCAAAGCAGC; DmdA-S266M-R (SEQ ID NO. 12):TCCTCCGGMMNGTTGCAGAATTTACCCAAACCGCATTC; DmdA-G317S random saturation mutant primers: DmdA-G317S-F (SEQ ID NO. 13): GGTCAAGTANKKAGCGCGATCCACAGTCCAGAATTCGGTGT; DmdA-G317S-R (SEQ ID NO. 14): TGGATCGCGCTMMNTACTTGACCTACCTGACGACCGT.

[0054] (2) Screening of saturated mutant libraries: Using the same induction expression, enzymatic reaction and screening methods as in Example 3, the saturated mutant libraries at each site were screened to obtain the optimal single-site mutants at each site. The screening results are shown in Table 2.

[0055] Table 2:

[0056] It can be seen that DmdA-T96I, DmdA-G317T, DmdA-N234L, DmdA-S266L, and DmdA-I135A are the mutants with the highest product concentration after the reaction among the saturation mutations at each site, and DmdA-T96I, DmdA-N234L, and DmdA-G317T are the top three best mutants.

[0057] (3) Site-specific combination mutation: Based on three core advantageous single-point mutants (T96I, N234L, and G317T) obtained through random saturation mutation screening, multi-site combination mutants were constructed using site-directed mutagenesis technology to clarify the synergistic enhancement effect of different mutation site combinations on DmdA enzyme activity. Specific site-directed combination mutant primers were designed using the recombinant plasmids of the optimal single-point mutants (T96I, N234L, and G317T) obtained through screening as templates.

[0058] Using the T96I recombinant plasmid as a template, the T96I-N234L dual-site combined mutant primers were: N234L-F (SEQ ID NO. 15): GTCCGAACCTGATCGAACGTGTTGAATCTGGTCTGCTGTC; N234L-R (SEQ ID NO. 16): TTCGATCAGGTTCGGACAGCCCGCACGAACGTTCAGATCT; Using the T96I recombinant plasmid as a template, the T96I-G317T dual-site combined mutation primers are as follows: G317T-F (SEQ ID NO. 17): CAAGTAACCAGCGCGATCCACAGTCCAGAATTCGGTG; G317T-R (SEQ ID NO. 18): TGGACTGTGGATCGCGCTGGTTACTTGACCTACCTGACGAC; Using the N234L recombinant plasmid as a template, the N234L-G317T dual-site combined mutation primers are as follows: Consistent with the primers for the T96I-G317T dual-site combination mutation; Using the T96I-N234L two-site combined mutant recombinant plasmid as a template, the T96I-N234L-G317T three-site combined mutant primers are as follows: Consistent with the primers for the T96I-G317T dual-site combination mutation; Site-directed mutagenesis PCR reaction: Using the corresponding single-point mutant and double-mutant recombinant plasmids as templates, the above-mentioned combination of mutant primers were added respectively, and PCR amplification was performed using a site-directed mutagenesis kit. The reaction system (25 μL) consisted of: 2.5 μL of 10× site-directed mutagenesis buffer, 2 μL of dNTP mixture (2.5 mmol / L), 1 μL of upstream primer (10 μmol / L), 1 μL of downstream primer (10 μmol / L), 1 μL of template plasmid, 0.5 μL of high-fidelity DNA polymerase (FastPfu rapid high-fidelity DNA polymerase - Beijing TransGenBiotech), and 17 μL of sterile deionized water.

[0059] PCR reaction conditions: 95℃ pre-denaturation for 3 min; 95℃ denaturation for 30 s, 60℃ annealing for 30 s, 72℃ extension for 5 min, for a total of 30 cycles; 72℃ final extension for 10 min to obtain recombinant plasmid PCR product containing combined mutation sites.

[0060] Plasmid digestion and transformation: PCR products were digested with DpnI restriction endonuclease at 37°C for 1 h to remove the template plasmid. The digested PCR products were transformed into *E. coli* DH5α competent cells, plated on LB agar containing kanamycin (50 μg / mL), and incubated at 37°C for 12 h. Single colonies were picked and cultured, plasmids were extracted and sequenced for verification. The precise introduction of the combined mutant sites was confirmed, with no other irrelevant mutations. Recombinant plasmids of the T96I-N234L, T96I-G317T, and N234L-G317T dual-site combined mutants and the T96I-N234L-G317T three-site combined mutant were obtained. The map of the T96I-N234L-G317T three-site combined mutant recombinant plasmid is shown below. Figure 2As shown, the expression vector used in this invention is pET-28a(+), which is a highly efficient prokaryotic inducible expression vector for Escherichia coli. It carries a strong T7 promoter and can achieve efficient transcription and inducible expression of the target gene using Escherichia coli BL21(DE3) strain. The vector contains Kan... + Kanamycin resistance selection markers facilitate stable screening and propagation of recombinant strains; they also have built-in His-Tag sequences that can be fused to express histidine tags, providing convenience for subsequent nickel column affinity purification of mutant proteins. They are a classic commercial vector for site-directed mutagenesis, heterologous expression, and functional screening of enzyme proteins.

[0061] The amino acid sequence of the three-site combined mutant T96I-N234L-G317T is shown in SEQ ID NO.19, the corresponding coding gene is shown in SEQ ID NO.20, and the tertiary structure is shown in... Figure 3 As shown in the tertiary structure model, the three mutation sites T96I, N234L, and G317T are distributed at the entrance of the methyl donor substrate binding pocket, around the tetrahydrofolate binding region, and in the flexible region of the protein's C-terminal backbone, respectively. T96I is located at the entrance of the methyl donor substrate pocket, and after mutation, it reshapes the hydrophobic microenvironment of the pocket, which is conducive to methyl donor binding. N234L is adjacent to the THF binding site and stabilizes the catalytic conformation of tetrahydrofolate through hydrophobic stacking, improving the precision of methyl transfer pairing. G317T is located on the C-terminal flexible ring backbone, introducing intramolecular hydrogen bonds to constrain the disordered movement of the peptide chain, improving the stability and acid-base tolerance of the mutant.

[0062] SEQ ID NO.19: MASIFPSRRVRRTPFSAGVEAAGVKGYTVYNHMLLPTVFDSLQADCAHLKEHVQVWDVACERQVSIQGPDALRLMKLISPRDMDRMADDQCYYVPIVDHRGGMLNDPVAVKLAADHYWLSLADGDLLQFGLGIAIARGFDVEIVEPDVSPLAVQGPRADDLMARVFGEAVRDIRFFRYKRLAF QGVELVVARSGWSKQGGFEIYVEGSELGMPLWNALFAAGADLNVRAGCPNLIERVESGLLSYGNDMTRENTPYECGLGKFCNSPEDYIGKAALAEQAKNGPARQIRALVIGGEIPPCQDAWPLLADGRQVGQVTSAIHSPEFGVNVAIGMVDRSHWAPGTGMEVETPDGMRPVTVREGFWRLE; SEQ ID NO.20:

[0063] Transformation and induced expression of recombinant plasmids: The recombinant plasmids of the verified combined mutants were transformed into Escherichia coli BL21(DE3) competent cells, plated on LB medium containing kanamycin (50 μg / mL), and cultured at 37°C for 12 h to obtain engineered combined mutants. The same induction expression conditions as in Example 3 (cultured at 37°C and 200 rpm until OD600 reached 0.8, 0.5 mmol / L IPTG was added, and expression was induced at 30°C for 12 h) to achieve high-efficiency expression of the DmdA gene of the combined mutants.

[0064] Enzyme activity verification of combined mutants: The enzyme activity of each combined mutant was detected using the same enzyme activity detection method as in Example 3. Wild type and each single-point mutant were used as controls. The product concentration and the enzyme activity increase ratio relative to wild type were calculated based on the liquid phase reaction results to verify the synergistic effect of different mutation sites. The detection results are shown in Table 3.

[0065] Table 3:

[0066] Results Analysis: The above test results show that the enzyme activity of each combination mutant is significantly higher than that of the corresponding single-site mutant and wild type. Among them, the three-site combination mutant T96I-N234L-G317T has the highest enzyme activity, which is 62.96% higher than that of wild type. This indicates that there is a significant synergistic effect among the three mutation sites T96I, N234L and G317T, which can synergistically improve the catalytic efficiency, substrate affinity and enzyme stability of DmdA enzyme, and provide core mutant resources for the subsequent construction of 5-MTHF high-efficiency synthetic engineered bacteria.

[0067] Example 5 Characterization of enzymatic properties of combined mutants: Using wild-type DmdA, the optimal single-site mutants (T96I, N234L, G317T), and three sets of two-site combined mutants as controls, the three-site superimposed mutant T96I-N234L-G317T of this invention was systematically characterized enzymatically, including optimal reaction temperature, kinetic parameters, molecular docking, and tertiary structure simulation determination, further elucidating the mechanism by which multi-site synergistic mutations improve enzyme structure and catalytic performance. All experimental data are the average of three parallel experiments, with a relative standard deviation (RSD) ≤ 5%.

[0068] (1) Determination of the optimal reaction temperature: A gradient reaction temperature was set at 25 ℃, 30 ℃, 37 ℃, 42 ℃, and 45 ℃. The reaction system was fixed at pH 7.4 PBS buffer, and the concentrations of tetrahydrofolate substrate, methyl donor substrate, and reaction time were kept consistent. Using the enzyme activity at 30 ℃ as 100%, the relative residual enzyme activities of wild-type, single-site mutant, two-site combined mutant, and three-site superimposed mutant were measured at different temperatures to investigate the temperature tolerance and catalytic temperature adaptability of different mutants. The results are shown in Table 4 below.

[0069] Table 4:

[0070] The results of relative enzyme activity assays under different temperature conditions show that the optimal reaction temperature for wild-type DmdA and most single- and double-site mutants is 30℃. The G317T single-site mutation, the T96I-G317T and N234L-G317T double-site mutations, and the T96I-N234L-G317T three-site combination mutants all maintain the highest relative enzyme activity in the 30℃–37℃ range, broadening the optimal temperature range to 30℃–37℃. These results indicate that G317T is the key mutation site causing the broadening of the enzyme's optimal temperature range; after introducing the G317T mutation, the mutant can still maintain 100% relative enzyme activity at 37℃, demonstrating improved high-temperature tolerance. The T96I and N234L single-point mutations themselves do not change the optimal temperature characteristics of the enzyme; the three-point combination mutants inherit the temperature performance advantages brought by G317T, and can catalyze efficiently in a wide temperature range of 30-37℃, which is more suitable for the actual working conditions of small temperature fluctuations in industrial catalysis.

[0071] (2) Deep learning predicts enzyme kinetic parameters A protein language model-driven kinetic prediction web server was used to virtually predict the kinetic parameters of wild-type DmdA and mutant sequences. The inputs were the enzyme amino acid sequence and the substrate SMILES structure. The reaction was set to pH 7.4 and temperature 30℃. The server's deep learning model output the virtually predicted Km(THF), Kcat, and Kcat / Km.

[0072] The enzyme kinetic parameters of the wild-type DmdA and T96I-N234L-G317T trisomy mutants are shown in Table 5. Table 5:

[0073] In summary, machine learning predictions show that the T96I-N234L-G317T mutant has a significantly increased Kcat, although Km is slightly increased and substrate affinity is slightly decreased. However, the overall catalytic specificity constant Kcat / Km is improved, and the overall catalytic performance is better than that of the wild type.

[0074] Example 6 Synthesis of 5-methyltetrahydrofolate using an in vitro enzyme catalysis system: An in vitro pure enzyme-coupled catalytic system was established, using folic acid as the initial substrate and purified wild-type and mutant DmdA as the main enzymes, combined with a reducing coenzyme, a precursor enzyme (fola enzyme), and a buffer system. Under controlled in vitro conditions, folic acid was continuously reduced to 5-methyltetrahydrofolate (5-MTHF). The in vitro catalytic efficiency of the T96I-N234L-G317T combined mutant was verified by comparing the catalytic yield and substrate conversion rate of different mutants.

[0075] Wild-type DmdA, single-site mutant, two-site mutant, and T96I-N234L-G317T three-site combination mutant enzyme solutions were purified by nickel column affinity chromatography and concentrated by ultrafiltration tubes, and the protein concentration was uniformly adjusted to 2 mg / mL. The total reaction system volume is 20 mL. It should be prepared and used immediately. The system components are shown in Table 6 below.

[0076] Table 6:

[0077] Blank control group: No fola enzyme solution or DmdA enzyme solution was added, and an equal amount of buffer solution was added. All other components were completely identical. This group was used to subtract spontaneous substrate reduction and background interference.

[0078] Catalytic reaction conditions: 30℃, 150rpm, protected from light and anaerobic, reaction time 10h. After the reaction, take 500ul of the reaction solution and add 500ul of methanol to completely inactivate the enzyme and terminate the reaction. Centrifuge at 12000 r / min for 3min, take the supernatant and filter it through a 0.22um organic filter membrane, dilute it 20 times and then detect it by HPLC.

[0079] L-5-methyltetrahydrofolate (L-5-MTHF) was quantitatively detected by high performance liquid chromatography (HPLC). A Yuexu C18 column (250 mm × 4.6 mm, 5 μm) was used; the column temperature was set to 40 °C, the injection volume to 10 μL, the flow rate to 1 mL / min, and the UV detector to 290 nm. Gradient elution mode was employed.

[0080] Mobile phase A is a 0.1% aqueous phosphoric acid solution, and mobile phase B is acetonitrile; gradient program: 0. 2 min, 98% A, 2% B; 2 12 min, linearly adjusted to 50% A, 50% B; 12 22 minutes, linear recovery to 98% A, 2% B; 22 Maintain column equilibration at 98% A and 2% B for 27 minutes. Use the external standard method to establish a standard curve based on the standards, and calculate the L-5-methyltetrahydrofolate content in the sample.

[0081] Substrate (folic acid) conversion rate: .

[0082] The liquid chromatography spectrum of the blank control group is as follows: Figure 4 9.257 min represents folic acid; the liquid chromatography pattern of the T96I-N234L-G317T mutant is as follows. Figure 5 The results were: 9.25 min for folic acid and 8.229 min for L-5-methyltetrahydrofolate; see Table 7 for the results.

[0083] Table 7:

[0084] The results show that the product concentration and folic acid substrate conversion rate of each mutant were higher than those of the wild type. The single-point mutant G317T has already brought about a significant catalytic improvement; the double-point mutants T96I-G317T and N234L-G317T further improved the conversion level; the three-point combination mutant T96I-N234L-G317T had the best performance, with a folic acid substrate conversion rate of 91.55% and a product L-5-methyltetrahydrofolate of 9.53 g / L. The results confirm that T96I, N234L, and G317T have a synergistic effect, and this three-point mutant has outstanding application potential in the in vitro cascade catalytic synthesis of L-5-methyltetrahydrofolate.

[0085] The above is a detailed description of the preferred embodiments of the present invention. However, the present invention is not limited to the embodiments described. Those skilled in the art can make various equivalent modifications or substitutions without departing from the spirit of the present invention. All such equivalent modifications or substitutions are included within the scope defined by the claims of the present invention.

Claims

1. A mutant of DmdA enzyme characterized in that, The mutant has any one of the following amino acid mutations in the amino acid sequence shown as SEQ ID NO. 2: T96I, T96A, T96C, T96L, T96V, T96Q, N234A, N234L, N234T, N234M, I135A, I135K, I135M, I135Q, S266M, S266E, S266L, G317S, G317T, G317V, G317W, G317L, G317I, T96I-N234L, T96I-G317T, N234L-G317T, T96I-N234L-G317T.

2. A nucleic acid molecule, characterized in that, It is a nucleic acid sequence encoding the DmdA enzyme mutant of claim 1.

3. A recombinant expression vector, characterized in that, The nucleic acid molecule of claim 2.

4. An engineered bacterium, characterized in that, The nucleic acid molecule of claim 2 and / or the recombinant expression vector of claim 3.

5. The engineered bacterium of claim 4, wherein, The engineered bacteria take E. coli, B. subtilis or C. glutamicum as host strains.

6. Use of the DmdA enzyme mutant of claim 1 or the engineered bacteria of any one of claims 4-5 in the preparation of 5-methyltetrahydrofolate.

7. A method for the preparation of 5-methyltetrahydrofolate, characterized in that, The DmdA enzyme mutant of claim 1 and dihydrofolate reductase are used to catalyze folate to prepare 5-methyltetrahydrofolate.

8. The method for preparing 5-methyltetrahydrofolate according to claim 7, characterized in that, The reaction system further comprises dimethyl mercaptopropionic acid inner salt and / or (2-carboxyethyl) dimethyl sulfonium chloride.

9. The method for preparing 5-methyltetrahydrofolate according to claim 7, characterized in that, The reaction system further comprises ADH enzyme, reducing agent and NADP+. The reaction system further comprises dimethyl mercaptopropionic acid inner salt and / or (2-carboxyethyl) dimethyl sulfonium chloride. The reaction system further comprises ADH enzyme, reducing agent and NADP+.